Speakers
Chris Baldwin, Vice President, Manufacturing & Supply, Resolution Therapeutics
Robert Balfour, Investment Director, Alsa Ventures
Ricardo Baptista, Chief Technology Officer, independent
Tomasz Baran, Executive VP, PBKM/FamiCord Group
Samantha Barber, Chief Executive Officer, Gene People
Roy Baynes, Senior Vice President Clinical Research, Eikon Therapeutics
Niklas Beschorner, Head of Rnd, PROVIREX Genome Editing Therapies GmbH
Anne Black, QA Specialist Pharmacist, NHS Specialist Pharmacy Service
Jaap Jan Boelens, Chief, Stem Cell Transplantation And Cellular Therapies Pediatrics, Memorial Sloan-Kettering Cancer Center
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics
John Bridgeman, Director of Cell Therapy Research, Instil Bio
Adam Brown, Co-founder and CTO, SynGenSys & Associate Professor of Biopharmaceutical Engineering, University of Sheffield
Alessia Cavazza, Group Leader and Assistant Professor in Gene Therapy, University College London
Fred Chereau, SVP, Strategy and Business Development, Alexion Pharmaceuticals
Klaus Cichutek, Former President, Paul Ehrlich Institute & Apl. Professor of Biochemistry, Goethe University Frankfurt
Angela Columbano, Head Business Development Partnership, GENETHON
Vicki Coutinho, Consultant, Geni Consulting
Eric Michael David, Chief Executive Officer, BridgeBio Gene Therapy
Francesco Dazzi, Professor of Regenerative Medicine, King’s College London Executive & Medical Lead, Cell Therapy, AstraZeneca
Carmen De Santo, Cruk New Investigator Fellow, Birmingham Centre for Railway Research and Education (UK &Dubai)
Colleen Delaney, Founder, Chief Scientific Officer, Deverra Therapeutics, Inc.
Victor Dillard, VP, Strategy & Operations, Resolution Therapeutics
Anne Douar, COO, Vivet Therapeutics
Marcus Droege, Senior Advisor, Market Access & Commercial, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Victoria English, Co-Founder And Editor, Evernow Publications
Marcie Finney, Executive Director, Cleveland Cord Blood Center
Gregory Fiore, Former CEO, Exacis Biotherapeutics
Katherine Forsey, Chief Research Officer, Charcot Marie Tooth Association
Miguel Forte, CEO, Kiji Tx
Gonzalo Garcia, Investment Partner, Syncona
Saba Ghassemi, Assistant Professor, University of Pennsylvania
Roberto Gramignoli, Associate Professor, Karolinska Institutet
Uta Griesenbach, Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy;, Imperial College London
Nagy Habib, Professor of Surgery, Imperial College London
eric Halioua, President & Chief Executive Officer, PDC*line pharma SA
Patrick Hanley, Chief and Director, Cellular Therapy Program, Children's National Medical Center
Melita Irving, Group Leader, University of Lausanne
Kathryn Ivey, Senior Vice President of Research, Tenaya Therapeutics
Ron Jortner, Founder & Chief Executive Officer, Aspire Biosciences
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
ANGELA JUSTICE, Chief People Officer / Executive Advisor, Justice Group Advisors
Cornelia Kasper, Head of Institute for Cell and Tissue Culture Technologies, University Of Natural Resources And Life Sciences Vienna
Sven Kili, Chief Development Officer, CCRM
Laura Koivusalo, Chief Executive Officer & Founder, StemSight
Bence Kozma, Research Assistant PostDoc, TU Wien
Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd
David Kuntin, Chief Executive Officer, MesenBio
Joanne Kurtzberg, Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures,, Duke University Medical Center
Lukasz Kwiatkowski, Product Development Supervisor, TC Biopharm
Holger Laux, Director of Viral Vector Process Development, CSL Behring
Daniel Lewi, Co-founder & Chief Executive Officer, The Cure & Action for Tay-Sachs (CATS) Foundation
Pauline L'Hénaff, Head of Industry Engagement, Access to Medicine Foundation
John Maher, CSO, Leucid Bio
Alberto Malerba, Lecturer in Gene Therapy, royal holloway university of london
Julius Mathews, Project Manager & Research Fellow, Fraunhofer Institute for Production Technology IPT
Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Director Translational Skills, LifeArc
Deana Mohr, Chief Executive Officer, MUVON Therapeutics
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
David Morrow, Senior Scientific Program Manager, EATRIS
Sophie Mountcastle, Network Manager - Innovation Hubs for Gene Therapies, Innovation Hubs for Gene Therapies
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Roberto Nitsch, Director, Astrazeneca
Kieran O'Donnell, Director, Kieran O'Donnell Ltd
Raphael Ognar, President & Chief Executive Officer, Co-Founder, NKILT Therapeutics Inc.
Dr Willy Oliveira, Project & Business Dev. Manager, Integra Therapeutics
Brian O'Mahony, Chief Executive Officer, Irish Haemophilia Society
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Dominic O'Regan, Business Development Consultant & Investor, New Mosaic
George Pamenter, PhD Researcher, UCL
Kerstin Papenfuss, Director Pharma, Deep Science Ventures
Shree Patel, EVP Patient Supply Operations, Achilles Therapeutics Limited
Kinnari Patel, President & COO, Rocket Pharma
Rik Patel, Senior Trade Manager, London & Partners
Tom Payne, Chief Operating Officer, Laverock Therapeutics
David Peritt, Founder and CSO, Lupagen
Trine Pilgaard, Director, Head of Market Access, Denmark and Iceland, Pfizer
Ana Plata, Head of Global Access, Respiratory & Immunology, AstraZeneca
Nicola Redfern, Director, NJ Redfern Ltd.
Jessica Robinson, PD, Terrapinn
Sean Russell, Head of Translational Project Management & Regulatory Affairs, Telethon Foundation
Tara Sadeghi, Chief Operating Officer, Cellenkos
Moin Saleem, Founder and Chief Scientific Advisor, PureSpring Therapeutics
Avencia Sánchez-Mejías García, Chief Executive Officer, Integra Therapeutics
Owen Smith, Partner, 4BIO Capital
Matthias Stöcker, Capability Lead, Boehringer-Ingelheim
Stephen Sullivan, COO, iPSirius
Marina Tarunina, Research Director, Plasticell
Anike Te, Chief Strategy Officer, Lucideon
Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Marco Traub, Chief Executive Officer, Tesct—Society
Sheela Upadhyaya, Life Science Advisor in Rare Diseases & Special Advisor, Openflex Ltd
Ketki Vispute, Associate Director of Production, Autolus
Ben Weil, Director of Manufacturing, INmune Bio
Theodora Weisz, Head of Patient Advocacy and Public Affairs, Novartis Gene Therapies, Novartis Gene Therapies
Anna Louisa Weltin, Research Fellow, Fraunhofer IPT
Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine, University of Reading
Chris Williams, Chief Business Officer, Autolus Therapeutics
Shao-An Xue, Senior Scientist, University College London
Mana Yen, Global Executive Director - Health systems, Novartis Gene Therapies
Get Involved with Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events